K2M Group Holdings Inc (KTWO) Given Consensus Recommendation of “Buy” by Analysts

K2M Group Holdings Inc (NASDAQ:KTWO) has earned an average rating of “Buy” from the fourteen analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $24.44.

Several research analysts have recently issued reports on KTWO shares. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $28.00 price objective on shares of K2M Group in a research report on Tuesday, October 10th. Oppenheimer set a $24.00 price objective on K2M Group and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Royal Bank of Canada reaffirmed a “buy” rating and set a $26.00 price objective on shares of K2M Group in a research report on Friday, September 22nd. Zacks Investment Research raised K2M Group from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Wednesday, October 4th. Finally, Wells Fargo & Co lowered their price objective on K2M Group from $28.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, October 10th.

K2M Group (NASDAQ KTWO) traded up $1.51 on Tuesday, reaching $20.70. The company had a trading volume of 665,600 shares, compared to its average volume of 451,540. K2M Group has a 1 year low of $16.44 and a 1 year high of $25.99. The firm has a market cap of $877.84, a PE ratio of -21.56 and a beta of 1.34. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.06 and a quick ratio of 1.67.

K2M Group (NASDAQ:KTWO) last released its earnings results on Wednesday, November 1st. The medical device company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.01). K2M Group had a negative return on equity of 16.02% and a negative net margin of 16.22%. The company had revenue of $62.65 million for the quarter, compared to analyst estimates of $62.69 million. During the same period in the previous year, the firm earned ($0.19) earnings per share. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. equities research analysts anticipate that K2M Group will post -0.85 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in KTWO. Schwab Charles Investment Management Inc. boosted its position in shares of K2M Group by 32.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 174,070 shares of the medical device company’s stock valued at $4,241,000 after purchasing an additional 42,290 shares during the period. First Trust Advisors LP acquired a new stake in shares of K2M Group in the 2nd quarter valued at about $1,270,000. Rhumbline Advisers boosted its position in shares of K2M Group by 49.2% in the 2nd quarter. Rhumbline Advisers now owns 43,165 shares of the medical device company’s stock valued at $1,051,000 after purchasing an additional 14,241 shares during the period. Legal & General Group Plc boosted its position in shares of K2M Group by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 9,561 shares of the medical device company’s stock valued at $232,000 after purchasing an additional 2,798 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its position in shares of K2M Group by 5,175.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock valued at $109,000 after purchasing an additional 4,399 shares during the period. 97.95% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first posted by BBNS and is the property of of BBNS. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/k2m-group-holdings-inc-ktwo-given-consensus-recommendation-of-buy-by-analysts/1820927.html.

K2M Group Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.